Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3996726 | 1.00 | ESR1 (0.56) | ESR1ESR2GRIN2BGRIN1POLB | |
| SCHEMBL229238 | 0.94 | ESR1 (0.51) | ESR1ESR2GRIN2BGRIN1POLB | |
| SCHEMBL229713 | 0.89 | ESR1 (0.53) | ESR1ESR2GRIN2BGRIN1POLB | |
| SCHEMBL225073 | 0.87 | ESR1 (0.46) | ESR1ESR2GRIN2BGRIN1CYP26A1 | |
| SCHEMBL228665 | 0.87 | ESR1 (0.55) | ESR1ESR2GRIN2BGRIN1POLB | |
| SCHEMBL230233 | 0.87 | ESR1 (0.55) | ESR1ESR2GRIN2BGRIN1POLB | |
| SCHEMBL228363 | 0.86 | ESR1 (0.57) | ESR1ESR2GRIN2BGRIN1POLB | |
| SCHEMBL14889420 | 0.86 | ESR1 (0.54) | ESR1ESR2GRIN2BGRIN1POLB | |
| SCHEMBL14889422 | 0.86 | ESR1 (0.54) | ESR1ESR2GRIN2BGRIN1POLB | |
| SCHEMBL227598 | 0.86 | ESR1 (0.51) | ESR1ESR2GRIN2BGRIN1CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933130-B2 | Treatment of vasomotor symptoms with selective estrogen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-01-13 | — | — | US | claimed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | claimed |
| EP-2037905-B1 | TREATMENT OF VASOMOTOR SYMPTOMS WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2013-05-01 | — | — | EP | claimed |
| US-20100105733-A1 | Treatment of vasomotor symptoms with selective estrogen receptor modulators | RADIUS HEALTH, INC. | 2010-04-29 | — | — | US | claimed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | claimed |
| US-8933130-B2 | Treatment of vasomotor symptoms with selective estrogen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-2037905-B1 | TREATMENT OF VASOMOTOR SYMPTOMS WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20100105733-A1 | Treatment of vasomotor symptoms with selective estrogen receptor modulators | RADIUS HEALTH, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885GRIN2B 1206/4885 |
| US-20100105733-A1 | Treatment of vasomotor symptoms with selective estrogen receptor modulators | GPER1, ESR1, SHBG | ESR1 2/4885ESR2 4/4885GRIN2B 1510/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | ESR1 34/4885ESR2 21/4885GRIN2B 3266/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885GRIN2B 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.